Min-Ju Kim

Min-Ju Kim

Auto-generated profile, based on publicly available information

Min-Ju Kim

Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Radiology
Verified
Journal Article
Closed access
JCJooae Choe
Jooae Choe
HHHye Jeon Hwang
Hye Jeon Hwang
JSJoon Beom Seo
Joon Beom Seo
SLSang Min Lee
Sang Min Lee
JYJihye Yun
Jihye Yun
BKByeongsoo Kim
Byeongsoo Kim
The proposed content-based image retrieval system is expected to assist in the diagnosis of interstitial lung disease in clinical practice regardless of experience level. Background Evaluation of interstitial lung disease (ILD) at CT is a challenging task that requires experience and is subject to substantial interreader variability. Purpose To investigate whether a...

1 January 2004 in Radiology
Verified
Journal Article
Closed access
DCDongil Choi
Dongil Choi
HLHyo K. Lim
Hyo K. Lim
MKMin Ju Kim
Min Ju Kim
SLSung Hoon Lee
Sung Hoon Lee
SKSeung Hoon Kim
Seung Hoon Kim
YKYong-Il Kim
Yong-Il Kim
PURPOSE: To evaluate the therapeutic efficacy and safety of percutaneous radiofrequency (RF) ablation for recurrent hepatocellular carcinoma (HCC) in the liver after hepatectomy.MATERIALS AND METHODS: Forty-five patients with 53 recurrent HCC tumors in the liver underwent percutaneous RF ablation with ultrasonographic guidance. All patients had a history of hepatic resection for HCC. The mean diameter of recurrent tumors was 2.1 cm (range, 0.8–4.0 cm). All patients were followed up for at least 10 months after ablation (range, 10–40 months; mean, 23 months). Therapeutic efficacy and complications were evaluated with multiphase helical computed tomography (CT) at regular follow-up visits. Overall and disease-free survival rates were calculated.RESULTS: At follow-up CT after initial RF ablation, 11 (21%) of 53 ablated HCC tumor sites showed residual tumor or local tumor progression. After additional RF ablation, complete ablation of 46 (87%) of 53 tumors was attained. Also at initial follow-up CT, before either additional RF ablation or other treatment was performed, 21 (47%) of 45 patients were found to have 41 new HCC tumors at other liver sites. Of these, nine tumors in eight patients were treatable with a second application of RF ablation. Overall survival rates at 1, 2, and 3 years were 82%, 72%, and 54%, respectively. No deaths or complications requiring further treatment occurred as a result of RF ablation.CONCLUSION: Percutaneous RF ablation is an effective and safe method for treating recurrent HCC in the liver after hepatectomy, with a good overall patient survival rate.© RSNA, 2003

1 April 2005 in American Journal of Roentgenology
Verified
Journal Article
Closed access
SKSeong Hyun Kim
Seong Hyun Kim
DCDongil Choi
Dongil Choi
SKSeung Hoon Kim
Seung Hoon Kim
JLJae Hoon Lim
Jae Hoon Lim
WLWon Jae Lee
Won Jae Lee
SLSoon Jin Lee
Soon Jin Lee
OBJECTIVE. We compared ferucarbotran-enhanced MRI with triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. SUBJECTS AND METHODS. Seventy-three consecutive patients with 121 hepatocellular carcinomas underwent ferucarbotran-enhanced MRI, including a dynamic study, and triple-phase MDCT before hepatic resection. The diagnosis of hepatocellular carcinoma was confirmed in all patients by means of pathologic examination after surgical resection. Three experienced radiologists independently reviewed the MR and CT images on a segment-by-segment basis. The accuracy of these techniques for the detection of hepatocellular carcinoma was assessed by conducting a receiver operating characteristic (ROC) analysis of the observations of 88 resected hepatic segments with at least one hepatocellular carcinoma each and 121 resected hepatic segments without hepatocellular carcinoma. RESULTS. The mean values of the area under the ROC curve (Az) for ferucarbotran-enhanced MRI and triple-phase MDCT for all observers were 0.947 and 0.949, respectively; the difference between these two values was not statistically significant (p = 0.799). The mean sensitivities of MRI and triple-phase MDCT were 90.2% and 91.3%, respectively, and their mean specificities were 97.0% and 95.3%, respectively. The differences in the mean sensitivities and specificities of these two imaging techniques were not statistically significant (p > 0.05 in each case). CONCLUSION. Ferucarbotran-enhanced MRI seems to be as accurate as triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

23 October 2017 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
SLSun-Ho Lee
Sun-Ho Lee
MKMin-Ju Kim
Min-Ju Kim
KCKiju Chang
Kiju Chang
ESEun Mi Song
Eun Mi Song
SHSung Wook Hwang
Sung Wook Hwang
BYByong Duk Ye
Byong Duk Ye
We aimed to evaluate the role of fecal calprotectin (FC) as a noninvasive marker for the disease activity of ulcerative colitis (UC) in a Korean cohort. A total of 181 fecal samples were collected from 181 consecutive UC patients between April 2015 and September 2016. FC levels were measured using the Quantum Blue® Calprotectin rapid test. The laboratory test results, partial Mayo Score (pMS), and colonoscopic imaging findings at FC level measurement were retrospectively reviewed. The Mayo endoscopic subscore (MES) and UC endoscopic index of severity (UCEIS) were graded by 2 certified endoscopists after training with 50 other cases. The FC levels were significantly correlated with pMS (Spearman correlation coefficient r = 0.428, p < 0.001), MES (r = 0.304, p < 0.001), UCEIS (r = 0.430, p < 0.001), and CRP (r = 0.379, p < 0.001). FC levels exhibited a significantly better correlation with UCEIS than with MES (Meng’s z = − 2.457, p = 0.01). The FC cut-off level of 187.0 mg/kg indicated complete mucosal healing (MES = 0; UCEIS =0) with a sensitivity and specificity of 0.857 and 0.891, respectively (area under the curve, 0.883; 95% confidence interval, 0.772–1.000). The FC level is significantly correlated with the clinical disease activity index, endoscopic indices, and serum inflammatory biomarkers in a Korean UC cohort. FC is highly predictive of complete mucosal healing in UC. UCEIS exhibits a stronger correlation with the FC level, as compared to MES. Thus, FC could be used as a reliable noninvasive indicator for evaluating disease activity and mucosal healing in UC.

11 March 2009 in FEBS Letters
Verified
Journal Article
Closed access
MKMin-Ju Kim
Min-Ju Kim
KAKyungsook Ahn
Kyungsook Ahn
SPSeong-Hoon Park
Seong-Hoon Park
HKHong-Jun Kang
Hong-Jun Kang
BJBong Geom Jang
Bong Geom Jang
JLJae-Yong Lee
Jae-Yong Lee

1 December 2015 in Critical Care
Verified
Journal Article
Open access
PDF file
JKJi-Yeon Kim
Ji-Yeon Kim
KJKyoungwoon Joung
Kyoungwoon Joung
KKKyung-Mi Kim
Kyung-Mi Kim
MKMin-Ju Kim
Min-Ju Kim
JKJoon-bum Kim
Joon-bum Kim
ICIn-Cheol Choi
In-Cheol Choi
Introduction: Saline-based and hydroxyethyl starch solutions are associated with increased risk of renal dysfunction. In the present study, we tested the hypothesis that balanced solutions and a limited volume of hydroxyethyl starch solution (renal protective fluid management [RPF] strategy) would decrease the incidence of postoperative acute kidney injury (AKI) and improve clinical outcomes in patients undergoing off-pump coronary artery bypass graft surgery (OPCAB). Methods: We investigated 783 patients who underwent elective OPCAB. All patients who underwent OPCAB between 1 January 2010 and 4 July 2012 formed the control group and were given intravenous fluids with saline-based solutions and unlimited volumes of colloid solutions. All patients who underwent OPCAB between 5 July 2012 and 31 December 2013 formed the RPF group and were given intravenous fluids with RPF. The primary outcome was the incidence of postoperative AKI. Secondary outcomes included the incidence of severe AKI, requirement for renal replacement therapy, renal outcome at the time of discharge, and other clinical outcomes. Results: Postoperative AKI occurred in 33 patients (14.4 %) in the RPF group compared with 210 patients (37.9 %) in the control group (P < 0.001). The incidences of severe AKI and persistent AKI after OPCAB were significantly lower, and the postoperative extubation time and duration of hospital stay were significantly shorter, in patients in the RPF group than in those in the control group. After adjustment by multivariate regression analyses and inverse probability of treatment weighting adjustment, the RPF group was independently associated with a lower incidence of postoperative AKI, severe AKI, and persistent AKI and a shorter postoperative extubation time and duration of hospital stay. Conclusions: The RPF strategy is associated with a significantly decreased incidence of postoperative, severe, and persistent AKI in patients undergoing OPCAB, although residual confounding may be present.